Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander T Cohen

Showing results (71-80 of 227) with videos related to

Pageof 23
Sort By:
Thrombosis and Haemostasis|June 4, 2020
Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. PerspectiveAlex C Spyropoulos, Walter Ageno, Alexander T Cohen, et al.
Thrombosis Journal|September 7, 2018
COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional studyAlexander T Cohen, Anthony Maraveyas, Jan Beyer-Westendorf, et al.
Future Oncology (London, England)|January 10, 2024
Effectiveness and safety of anticoagulants among patients with venous thromboembolism and common cancers or cancers with high venous thromboembolism riskAlexander T Cohen, Virginia Noxon, Amol D Dhamane, et al.
Thrombosis and Haemostasis|July 1, 2010
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response studyGary Raskob, Alexander T Cohen, Bengt I Eriksson, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 11, 2020
A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial FibrillationNathan R Hill, Belinda Sandler, Evelien Bergrath, et al.
American Heart Journal|December 16, 2014
Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendmentAlexander T Cohen, Robert Harrington, Samuel Z Goldhaber, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|February 16, 2024
Agreement between 30-day and 90-day modified Rankin Scale score and utility-weighted modified Rankin Scale score in acute intracerebral hemorrhage: An analysis of ATACH-2 trial dataCraig I Coleman, Mauricio Concha, William L Baker, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 16, 2024
Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous ThromboembolismAlexander T Cohen, Amol D Dhamane, Xuejun Liu, et al.
Vascular Medicine (London, England)|July 10, 2007
Thromboprophylaxis with dalteparin in medical patients: which patients benefit?Alexander T Cohen, Alexander G G Turpie, Alain Leizorovicz, et al.
Thrombosis and Haemostasis|January 5, 2005
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patientsPaul T Vaitkus, Alain Leizorovicz, Alexander T Cohen, et al.
Pageof 23

Showing results (71-80 of 227) with videos related to

Sort By:
Pageof 23
Thrombosis and Haemostasis|June 4, 2020
Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. PerspectiveAlex C Spyropoulos, Walter Ageno, Alexander T Cohen, et al.
Thrombosis Journal|September 7, 2018
COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional studyAlexander T Cohen, Anthony Maraveyas, Jan Beyer-Westendorf, et al.
Future Oncology (London, England)|January 10, 2024
Effectiveness and safety of anticoagulants among patients with venous thromboembolism and common cancers or cancers with high venous thromboembolism riskAlexander T Cohen, Virginia Noxon, Amol D Dhamane, et al.
Thrombosis and Haemostasis|July 1, 2010
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response studyGary Raskob, Alexander T Cohen, Bengt I Eriksson, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 11, 2020
A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial FibrillationNathan R Hill, Belinda Sandler, Evelien Bergrath, et al.
American Heart Journal|December 16, 2014
Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendmentAlexander T Cohen, Robert Harrington, Samuel Z Goldhaber, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|February 16, 2024
Agreement between 30-day and 90-day modified Rankin Scale score and utility-weighted modified Rankin Scale score in acute intracerebral hemorrhage: An analysis of ATACH-2 trial dataCraig I Coleman, Mauricio Concha, William L Baker, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 16, 2024
Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous ThromboembolismAlexander T Cohen, Amol D Dhamane, Xuejun Liu, et al.
Vascular Medicine (London, England)|July 10, 2007
Thromboprophylaxis with dalteparin in medical patients: which patients benefit?Alexander T Cohen, Alexander G G Turpie, Alain Leizorovicz, et al.
Thrombosis and Haemostasis|January 5, 2005
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patientsPaul T Vaitkus, Alain Leizorovicz, Alexander T Cohen, et al.
Pageof 23